This was quite a week in biotechnology. You had a major premium buyout and had much data come out from the American Society of Clinical Oncology (ASCO) and others. This is far from all of the movers, but it is a brief summary of the major gainers from BioHealthInvestor.com showing how large some moves were in biotechnology this week.
Acorda Therapeutics Inc. (NASDAQ: ACOR) had a great week after it announced positive data from a second Phase III study of its Fampridine-SR for patients' walking abilities who suffer from multiple sclerosis (MS). FULL DETAILS
Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL) was a strange stock this week. The company reported great news but shares slid before the market figured out it had misinterpreted news in the company. INITIAL DETAILS
Inspire Pharmaceuticals Inc. (NASDAQ: ISPH) saw a surge after it reached its primary endpoint in Phase III trial of Denufosol for Cystic Fibrosis. FULL DETAILS
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) saw a very mixed week after two weeks of high volatility. Here we conducted a full 180-degree view covering the upside of the stock and the negative side of the stock. FULL DETAILS
Oncolytics Biotech Inc. (NASDAQ: ONCY) saw gains after the Canadian biotech released positive data on its Phase II studies of intravenous REOLYSIN® in patients with sarcomas metastatic to the lung (lung cancer). FULL DETAILS
Pharmacyclics Inc. (NASDAQ: PCYC) shares moved up impressively after its Phase 1/2 trial of motexafin gadolinium plus antibody targeted radiation therapy demonstrated a high complete response rate in patients with non-Hodgkin's lymphoma. FULL DETAILS
Sequenom Inc. (NASDAQ: SQNM) saw a very positive reaction after the genetic analysis solution company announced its progress with a non-invasive technology that detects Down syndrome in a mother's blood analysis. FULL DETAILS
Tercica, Inc. (NASDAQ: TRCA) is yet another small cap biotech that received a huge premium acquisition from a foreign buyer, with a 104% premium to the prior close and a 74% premium to the 3-month average. FULL DETAILS
Jon Ogg is an editor and partner of 247WallSt.com, which owns BioHealthInvestor.com.
Nuclear power is on the comeback trail
Apple backs AT&T in continuing spat with Verizon
Closing Bell: The recession is still over, still... do you feel it?
